个性化延迟抗凝用于减少全关节置换术后瘀斑患者围术期出血的安全性和有效性研究

注册号:

Registration number:

ChiCTR2400084440 

最近更新日期:

Date of Last Refreshed on:

2024-12-27 19:16:53 

注册时间:

Date of Registration:

2024-05-16 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

个性化延迟抗凝用于减少全关节置换术后瘀斑患者围术期出血的安全性和有效性研究

Public title:

Safety and efficacy of personalized delayed anticoagulation in reducing perioperative bleeding in patients with ecchymosis after total joint arthroplasty

注册题目简写:

English Acronym:

研究课题的正式科学名称:

个性化延迟抗凝用于减少全关节置换术后瘀斑患者围术期出血的安全性和有效性研究

Scientific title:

Safety and efficacy of personalized delayed anticoagulation in reducing perioperative bleeding in patients with ecchymosis after total joint arthroplasty

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

罗雪峰 

研究负责人:

黄伟 

Applicant:

Luo Xuefeng 

Study leader:

Huang Wei 

申请注册联系人电话:

Applicant telephone:

+86 178 1537 1407

研究负责人电话:

Study leader's
telephone:

+86 23 8901 1202

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

568633163@qq.com

研究负责人电子邮件:

Study leader's E-mail:

huangjiaxingys@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

重庆市渝中区友谊路1号

研究负责人通讯地址:

重庆市渝中区友谊路1号

Applicant address:

1 Youyi Road, Yuzhong District, Chongqing, China

Study leader's address:

1 Youyi Road, Yuzhong District, Chongqing, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

重庆医科大学附属第一医院

Applicant's institution:

The First Affiliated Hospital of Chongqing Medical University

研究负责人所在单位:

重庆医科大学附属第一医院

Affiliation of the Leader:

The First Affiliated Hospital of Chongqing Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2024-194-01

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

重庆医科大学附属第一医院伦理委员会

Name of the ethic committee:

Ethics Committee of the First Affiliated Hospital of Chongqing Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2024-03-25 00:00:00

伦理委员会联系人:

罗天友

Contact Name of the ethic committee:

Luo Tianyou

伦理委员会联系地址:

重庆市渝中区友谊路1号

Contact Address of the ethic committee:

1 Youyi Road, Yuzhong District, Chongqing, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 23 8901 1019

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

重庆医科大学附属第一医院

Primary sponsor:

The First Affiliated Hospital of Chongqing Medical University

研究实施负责(组长)单位地址:

重庆市渝中区友谊路1号

Primary sponsor's address:

1 Youyi Road, Yuzhong District, Chongqing, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

重庆市

市(区县):

Country:

China

Province:

Chong Qing

City:

单位(医院):

重庆医科大学附属第一医院

具体地址:

重庆医科大学附属第一医院

Institution
hospital:

The First Affiliated Hospital of Chongqing Medical University

Address:

1 Youyi Road, Yuzhong District, Chongqing, China

经费或物资来源:

重庆医科大学附属第一医院

Source(s) of funding:

The First Affiliated Hospital of Chongqing Medical University

研究疾病:

瘀斑  

Target disease:

ecchymosis

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

治疗新技术临床试验 

Study phase:

New Treatment Measure Clinical Study

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

研究结果可为相关患者围手术期血液管理提供个性化建议,减少围术期瘀斑加重及减少围术期出血,有重要的临床指导意义  

Objectives of Study:

The results can provide personalized suggestions for perioperative blood management of related patients, reduce perioperative ecchymosis aggravation and perioperative bleeding, and have important clinical guiding significance

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1)合并严重心脑血管疾病(心肌梗死、脑梗死等); 2)有明显的出血倾向(如胃肠道活动性出血、脑出血等); 3)合并全身或局部静脉血栓栓塞症(如深静脉血栓形成、肺栓塞等); 4)既往明确的凝血功能障碍; 5)合并严重的神经肌肉系统疾病; 6)接受双侧TKA/THA或翻修TKA/THA 7)怀孕或者哺乳的;

Exclusion criteria:

1) Complicated with severe cardiovascular and cerebrovascular diseases (myocardial infarction, cerebral infarction, etc.); 2) There is a significant bleeding tendency (such as gastrointestinal active bleeding, cerebral hemorrhage, etc.); 3) Combined with systemic or local venous thromboembolism (such as deep vein thrombosis, pulmonary embolism, etc.); 4) Previously defined coagulation dysfunction; 5) Complicated with severe neuromuscular system diseases; 6) Receive a bilateral TKA/THA or a renovated TKA/THA 7) Pregnant or breastfeeding;

研究实施时间:

Study execute time:

From 2024-04-01 00:00:00 To 2026-04-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2024-05-20 00:00:00 To 2026-04-01 00:00:00

干预措施:

Interventions:

组别:

瘀斑个性化延迟抗凝组

样本量:

50

Group:

Ecchymosis individualized delayed anticoagulation group

Sample size:

干预措施:

瘀斑患者延迟使用抗凝剂

干预措施代码:

Intervention:

Delayed use of anticoagulants in patients with ecchymosis

Intervention code:

组别:

瘀斑患者常规抗凝组

样本量:

50

Group:

Patients with ecchymosis routine anticoagulation group

Sample size:

干预措施:

常规抗凝治疗

干预措施代码:

Intervention:

Routine anticoagulation treatment

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

重庆 

市(区县):

渝中 

Country:

China

Province:

Chongqing

City:

Yuzhong

单位(医院):

重庆医科大学附属第一医院 

单位级别:

三甲 

Institution
hospital:

The First Affiliated Hospital of Chongqing Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

血常规

指标类型:

主要指标

Outcome:

Blood routine examination

Type:

Primary indicator

测量时间点:

术前和术后

测量方法:

Measure time point of outcome:

Preoperative and postoperative

Measure method:

指标中文名:

凝血象

指标类型:

主要指标

Outcome:

coagulogram

Type:

Primary indicator

测量时间点:

术前和术后

测量方法:

Measure time point of outcome:

Preoperative and postoperative

Measure method:

指标中文名:

血栓弹力图

指标类型:

主要指标

Outcome:

thromboelastogram

Type:

Primary indicator

测量时间点:

术前和术后

测量方法:

Measure time point of outcome:

Preoperative and postoperative

Measure method:

指标中文名:

围术期静脉血栓栓塞症(VTE):深静脉血栓(DVT)和肺栓塞(PE)

指标类型:

主要指标

Outcome:

Perioperative venous thromboembolism (VTE): deep vein thrombosis (DVT) and pulmonary embolism (PE)

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

手术相关并发症

指标类型:

次要指标

Outcome:

Surgical related complications

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

患者基线信息

指标类型:

附加指标

Outcome:

patient baseline data

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

手术相关信息

指标类型:

附加指标

Outcome:

surgery-related data

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 70 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

廖军义医生使用中央随机化系统(IWRS)进行电脑随机,分配至试验组、对照组。

Randomization Procedure (please state who generates the random number sequence and by what method):

Dr. Liao Junyi performed computer randomization using the Central randomization system (IWRS) and assigned them to the experimental group and the control group.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

单盲

Blinding:

single blind

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

2026年04月,青蜂临床试验电子数据采集系统,http://edc.blueballon.cn/login

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

April,2026; http://edc.blueballon.cn/login

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

EDC。骨科临床数据库

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

EDC. Orthopaedic surgery database

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2024-05-16 16:27:46